NATIONAL INSTITUTES OF HEALTH

CHIP and mCAs increase breast cancer risk and colorectal cancer mortality. CHIP linked to higher breast cancer risk (HR, 1.30; 95% CI, 1.03-1.64; P =.02) and colorectal cancer death (HR, 2.50; 95% CI, 1.32-4.72; P = .004). mCAs with cell fraction >5% raise breast cancer risk (HR, 1.39; 95% CI, 1.06-1.83; P =.01) and colon cancer death (HR, 2.19; 95% CI, 1.11-4.3; P =.02).

NIH report provides 17 recommendations to improve NEC scientific evidence, emphasizing prevention of preterm birth as key to reducing NEC. The report highlights gaps in understanding NEC's development, particularly in relation to feeding practices and human milk's role. Additional research is needed to optimize nutrition and feeding methods for preterm infants, enhance milk production, and reduce disparities in lactation and donor milk access.

New research finds that following the MIND diet for 10 years significantly reduces the risk of cognitive decline, with women experiencing a 6% lower risk. The diet combines elements of the Mediterranean and DASH diets, emphasizing brain-healthy foods while limiting unhealthy ones.

Clarivate Plc unveils Citation Laureates 2024, forecasting Nobel Prize recipients based on extraordinary citation records and societal impact. This year's 22 laureates span six countries and have made significant contributions to fields like clean energy, nanotechnology, and quantum computing.

Oregon State University researchers received a $1.2 million NIH grant to develop an AI-powered device using saliva analysis for personalized epilepsy treatment, aiming to optimize anti-seizure medication dosing and reduce side effects.

A NIH-supported trial found pomalidomide, a bone marrow cancer drug, effective in treating hereditary hemorrhagic telangiectasia (HHT), reducing nosebleeds and improving quality of life. Published in the New England Journal of Medicine, the trial was stopped early due to significant positive results, offering hope for HHT patients who previously had no reliable treatment.

Pomalidomide, approved for multiple myeloma, significantly reduces severe nosebleeds in HHT patients, improving quality of life, according to the PATH-HHT study published in the New England Journal of Medicine.

A clinical trial led by Keith McCrae, M.D., at Cleveland Clinic demonstrated that pomalidomide, a cancer drug, is safe and effective for treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder. The trial, supported by the National Institutes of Health, was stopped early due to successful findings and published in the New England Journal of Medicine. Pomalidomide significantly reduced nosebleed severity, required fewer blood transfusions, and improved quality of life for HHT patients.

Lack of funding and understanding of long COVID's mechanisms hinder drug development, frustrating patients and researchers. Despite initial positive results with Ampligen, Aim ImmunoTech faced funding challenges. The NIH's RECOVER initiative focuses on observational studies rather than new compounds, and private investors avoid long COVID due to perceived risk. Small biotech companies struggle to sustain research efforts, with some shifting focus or shutting down. Public-private partnerships and increased federal funding are suggested as solutions to advance long COVID treatment research.

Thomas A. Russo identified genetic elements transforming classical Klebsiella pneumoniae into hypervirulent strains, which can infect healthy people and become drug-resistant. Research published in eBioMedicine highlights pVir plasmid as the primary genetic determinant of hypervirulence, with potential therapeutic targets for countermeasures.